| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 57.05M | 41.82M | 7.57M | 9.69M | 1.58M | 0 |
| Revenue Growth % | - | - | - | -0.27% | -0.82% | 0.28% | -0.84% | -1% |
| Cost of Goods Sold | 0 | 666K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | -666K | 57.05M | 41.82M | 7.57M | 9.69M | 1.58M | 0 |
| Gross Margin % | - | - | 1% | 1% | 1% | 1% | 1% | - |
| Gross Profit Growth % | - | - | 86.66% | -0.27% | -0.82% | 0.28% | -0.84% | -1% |
| Operating Expenses | 18.35M | 30.91M | 58.28M | 83.46M | 105.11M | 136.88M | 185.72M | 228.37M |
| OpEx % of Revenue | - | - | 1.02% | 2% | 13.88% | 14.13% | 117.55% | - |
| Selling, General & Admin | 3.82M | 6.5M | 10.93M | 17.27M | 27.56M | 39.95M | 57.93M | 59.05M |
| SG&A % of Revenue | - | - | 0.19% | 0.41% | 3.64% | 4.12% | 36.66% | - |
| Research & Development | 14.53M | 24.41M | 47.35M | 66.19M | 77.55M | 96.94M | 127.8M | 169.31M |
| R&D % of Revenue | - | - | 0.83% | 1.58% | 10.24% | 10.01% | 80.88% | - |
| Other Operating Expenses | 0 | -49K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.35M | -30.91M | -1.23M | -41.65M | -97.53M | -127.2M | -184.15M | -228.37M |
| Operating Margin % | - | - | -0.02% | -1% | -12.88% | -13.13% | -116.55% | - |
| Operating Income Growth % | - | -0.68% | 0.96% | -32.83% | -1.34% | -0.3% | -0.45% | -0.24% |
| EBITDA | -18.06M | -30.25M | -118K | -40.34M | -96M | -123.52M | -182.3M | -226.24M |
| EBITDA Margin % | - | - | -0% | -0.96% | -12.68% | -12.75% | -115.38% | - |
| EBITDA Growth % | - | -0.68% | 1% | -340.82% | -1.38% | -0.29% | -0.48% | -0.24% |
| D&A (Non-Cash Add-back) | 292K | 666K | 1.11M | 1.31M | 1.53M | 3.68M | 1.84M | 2.13M |
| EBIT | -18.35M | -30.91M | -1.23M | -41.65M | -97.26M | -122.53M | -160.07M | -207.28M |
| Net Interest Income | 0 | 0 | 600K | 112K | 272K | 3.88M | 22.81M | 18.06M |
| Interest Income | 16K | 688K | 816K | 478K | 272K | 4.67M | 24.08M | 21.09M |
| Interest Expense | 0 | 0 | 216K | 366K | 0 | 791K | 1.27M | 3.02M |
| Other Income/Expense | 16K | 639K | 600K | 112K | 272K | 3.88M | 22.81M | 18.06M |
| Pretax Income | -18.33M | -30.28M | -631K | -41.53M | -97.26M | -123.32M | -161.34M | -210.3M |
| Pretax Margin % | - | - | -0.01% | -0.99% | -12.85% | -12.73% | -102.11% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.12% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -20.62M | -30.28M | -631K | -41.53M | -97.26M | -123.32M | -161.34M | -210.3M |
| Net Margin % | - | - | -0.01% | -0.99% | -12.85% | -12.73% | -102.11% | - |
| Net Income Growth % | - | -0.47% | 0.98% | -64.82% | -1.34% | -0.27% | -0.31% | -0.3% |
| Net Income (Continuing) | -18.33M | -30.28M | -631K | -41.53M | -97.26M | -123.32M | -161.34M | -210.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -25.67 | -1.83 | 0.01 | -1.17 | -2.71 | -2.94 | -2.75 | -3.47 |
| EPS Growth % | - | 0.93% | 1% | - | -1.32% | -0.08% | 0.06% | -0.26% |
| EPS (Basic) | -25.67 | -1.83 | 0.01 | -1.17 | -2.71 | -2.94 | -2.75 | -3.47 |
| Diluted Shares Outstanding | 803.5K | 16.51M | 35.55M | 35.55M | 35.85M | 42.02M | 58.72M | 60.54M |
| Basic Shares Outstanding | 803.5K | 16.51M | 35.55M | 35.55M | 35.85M | 42.02M | 58.72M | 60.54M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.71M | 61.73M | 111.9M | 290.75M | 209.44M | 340.31M | 505.5M | 362.26M |
| Cash & Short-Term Investments | 4.25M | 60.95M | 102.77M | 276.89M | 200.6M | 331.19M | 494.25M | 355.72M |
| Cash Only | 4.25M | 60.95M | 85.81M | 50.88M | 51.66M | 33.69M | 63.23M | 71.19M |
| Short-Term Investments | 0 | 0 | 16.97M | 226.01M | 148.93M | 297.5M | 431.01M | 284.54M |
| Accounts Receivable | 0 | 500K | 7.38M | 9.36M | 2.47M | 3.14M | 3M | 2.3M |
| Days Sales Outstanding | - | - | 47.25 | 81.72 | 118.87 | 118.49 | 692.34 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 250K | 0 | 0 | 0 | 156K | 173K | 1.27M | 163K |
| Total Non-Current Assets | 1.85M | 4.8M | 7.16M | 4.77M | 11.77M | 10.3M | 6.65M | 34.69M |
| Property, Plant & Equipment | 1.85M | 4.26M | 4.08M | 4.32M | 10.94M | 9.91M | 4.78M | 32.77M |
| Fixed Asset Turnover | - | - | 13.99x | 9.68x | 0.69x | 0.98x | 0.33x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 536K | 3.08M | 451K | 838K | 394K | 1.87M | 1.92M |
| Total Assets | 6.55M | 66.53M | 119.06M | 295.53M | 221.22M | 350.61M | 512.15M | 396.95M |
| Asset Turnover | - | - | 0.48x | 0.14x | 0.03x | 0.03x | 0.00x | - |
| Asset Growth % | - | 9.15% | 0.79% | 1.48% | -0.25% | 0.58% | 0.46% | -0.22% |
| Total Current Liabilities | 3.19M | 5.08M | 8.17M | 11.6M | 16.83M | 23.91M | 28.52M | 33.22M |
| Accounts Payable | 1.59M | 2.58M | 1.25M | 2.02M | 2.97M | 1.58M | 4.53M | 5.96M |
| Days Payables Outstanding | - | 1.41K | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 130K | 3.04M | 4.63M | 5.22M | 7.2M | 9.04M | 0 |
| Current Ratio | 1.48x | 12.14x | 13.69x | 25.07x | 12.44x | 14.23x | 17.72x | 10.91x |
| Quick Ratio | 1.48x | 12.14x | 13.69x | 25.07x | 12.44x | 14.23x | 17.72x | 10.91x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 62.33M | 111.33M | 866K | 5.33M | 13.36M | 10.05M | 59.65M |
| Long-Term Debt | 0 | 525K | 0 | 0 | 0 | 9.93M | 10.05M | 30.21M |
| Capital Lease Obligations | 0 | 525K | 444K | 0 | 5.33M | 3.43M | 0 | 29.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 61.28M | 110.88M | 866K | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.19M | 67.41M | 119.5M | 12.46M | 22.16M | 37.27M | 38.58M | 92.87M |
| Total Debt | 0 | 525K | 444K | 0 | 7.19M | 15.81M | 11.37M | 60.19M |
| Net Debt | -4.25M | -60.42M | -85.36M | -50.88M | -44.47M | -17.87M | -51.86M | -11M |
| Debt / Equity | - | - | - | - | 0.04x | 0.05x | 0.02x | 0.20x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -5.70x | -113.78x | - | -160.81x | -145.34x | -75.52x |
| Total Equity | 3.35M | -882K | -435K | 283.06M | 199.06M | 313.34M | 473.58M | 304.08M |
| Equity Growth % | - | -1.26% | 0.51% | 651.71% | -0.3% | 0.57% | 0.51% | -0.36% |
| Book Value per Share | 4.16 | -0.05 | -0.01 | 7.96 | 5.55 | 7.46 | 8.07 | 5.02 |
| Total Shareholders' Equity | 3.35M | -882K | -435K | 283.06M | 199.06M | 313.34M | 473.58M | 304.08M |
| Common Stock | 1K | 1K | 1K | 3K | 3K | 5K | 6K | 6K |
| Retained Earnings | -36.57M | -71.47M | -76.3M | -117.83M | -215.09M | -338.41M | -499.75M | -710.05M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -1.07M | -1K | -32K | -201K | -1.96M | 345K | 321K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.92M | -28.33M | -2.75M | -37.27M | -75.44M | -94.63M | -116.36M | -155.5M |
| Operating CF Margin % | - | - | -0.05% | -0.89% | -9.96% | -9.77% | -73.65% | - |
| Operating CF Growth % | - | -0.67% | 0.9% | -12.55% | -1.02% | -0.25% | -0.23% | -0.34% |
| Net Income | -18.33M | -30.28M | -631K | -41.53M | -97.26M | -123.32M | -161.34M | -210.3M |
| Depreciation & Amortization | 292K | 666K | 1.11M | 1.31M | 1.53M | 1.82M | 1.84M | 2.13M |
| Stock-Based Compensation | 33K | 228K | 1.83M | 3.9M | 10.44M | 22.6M | 44.48M | 37.63M |
| Deferred Taxes | 0 | 0 | -12.2M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 191K | 1.05M | 12.2M | 266K | 2.93M | 52K | -2.6M | 5.96M |
| Working Capital Changes | 893K | 1.05M | -5.06M | -1.21M | 6.92M | 4.22M | 1.25M | 9.09M |
| Change in Receivables | 0 | -250K | -7.05M | -2.23M | 7.28M | 15K | 1.98M | 0 |
| Change in Inventory | 0 | 0 | 3.2M | 113K | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 760K | -1.25M | 922K | 891K | -1.35M | 2.97M | 1.43M |
| Cash from Investing | -1.41M | -2.32M | -17.93M | -210.87M | 73.7M | -150.2M | -127.01M | 140.34M |
| Capital Expenditures | -1.41M | -2.32M | -964K | -1.53M | -1.95M | -1.76M | -921K | -3.85M |
| CapEx % of Revenue | - | - | 0.02% | 0.04% | 0.26% | 0.18% | 0.58% | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -254K | -209.33M | 75.65M | -148.44M | 0 | 0 |
| Cash from Financing | 20.01M | 87.35M | 45.54M | 213.21M | 2.53M | 226.85M | 274.4M | 23.12M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 20.02M | 87.35M | -2.58M | 0 | -457K | 1.21M | 5M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -18.33M | -30.65M | -3.71M | -38.8M | -77.4M | -96.39M | -117.28M | -159.35M |
| FCF Margin % | - | - | -0.07% | -0.93% | -10.22% | -9.95% | -74.23% | - |
| FCF Growth % | - | -0.67% | 0.88% | -9.45% | -0.99% | -0.25% | -0.22% | -0.36% |
| FCF per Share | -22.81 | -1.86 | -0.10 | -1.09 | -2.16 | -2.29 | -2.00 | -2.63 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.94x | 4.36x | 0.90x | 0.78x | 0.77x | 0.72x | 0.74x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -616.5% | -2458.47% | - | -29.39% | -40.35% | -48.13% | -41% | -54.09% |
| Return on Invested Capital (ROIC) | - | - | - | -42.67% | -37.83% | -42.39% | -38.51% | -47.92% |
| Gross Margin | - | - | 100% | 100% | 100% | 100% | 100% | - |
| Net Margin | - | - | -1.11% | -99.32% | -1284.51% | -1273.32% | -10211.14% | - |
| Debt / Equity | - | - | - | - | 0.04x | 0.05x | 0.02x | 0.20x |
| Interest Coverage | - | - | -5.70x | -113.78x | - | -160.81x | -145.34x | -75.52x |
| FCF Conversion | 0.82x | 0.94x | 4.36x | 0.90x | 0.78x | 0.77x | 0.72x | 0.74x |
| Revenue Growth | - | - | - | -26.7% | -81.89% | 27.91% | -83.69% | -100% |
Pliant Therapeutics, Inc. (PLRX) saw revenue decline by 100.0% over the past year.
Pliant Therapeutics, Inc. (PLRX) reported a net loss of $175.5M for fiscal year 2024.
Pliant Therapeutics, Inc. (PLRX) has a return on equity (ROE) of -54.1%. Negative ROE indicates the company is unprofitable.
Pliant Therapeutics, Inc. (PLRX) had negative free cash flow of $158.8M in fiscal year 2024, likely due to heavy capital investments.